59 results
CORRESP
FLGT
Fulgent Genetics Inc
9 Jan 24
Correspondence with SEC
12:00am
. This is currently the lead drug candidate under therapeutic development that has the majority of the $15M budget, which was initially set by the CEO
8-K
EX-10.1
gf3v7 lty
18 May 23
Departure of Directors or Certain Officers
4:05pm
DEFA14A
0mnsmf92wcvwva4x
31 Mar 23
Additional proxy soliciting materials
9:58pm
8-K
EX-2.1
it23o3l 6ug31
26 Apr 22
Completion of Acquisition or Disposition of Assets
4:43pm
8-K
m76gez0o
18 Apr 22
Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results
4:13pm
8-K
EX-99.1
09z afnhmg8
4 Mar 21
Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
4:07pm